Clinical Trials Logo
NCT number NCT00262990
Study type Interventional
Source Novartis
Status Completed
Phase Phase 3
Start date November 2005

Clinical Trial Summary

The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03203993 - China Ovarian Cancer BRCA Testing Study N/A
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Active, not recruiting NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Active, not recruiting NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
Not yet recruiting NCT03180307 - OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer Phase 3
Not yet recruiting NCT03249142 - Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer Phase 1/Phase 2
Not yet recruiting NCT03197584 - QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy Phase 1/Phase 2
Recruiting NCT02928549 - Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study N/A
Recruiting NCT03010124 - Prognostic and Predictive Biomarkers in Ovarian Cancers N/A
Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Recruiting NCT02891824 - ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab Phase 3
Recruiting NCT02855944 - ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Phase 3
Recruiting NCT02545010 - Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer Phase 1
Recruiting NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Recruiting NCT02526017 - Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT02560818 - Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer N/A
Recruiting NCT02560337 - Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. Phase 2
Active, not recruiting NCT02948075 - Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy Phase 2
Recruiting NCT01690468 - PTX-200 and Carboplatin in Ovarian Cancer Phase 1/Phase 2